The Systems Biology of Drug Resistance in Cancer group, led by professor Sampsa Hautaniemi, focuses on understanding and finding effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., analyze molecular & clinical data from cancer patients with machine learning and mathematical methods, to identify efficient patient-specific therapeutic targets. Our work is cross-disciplinary and done in close collaboration with researchers from various disciplines, including clinicians, cell biologists and geneticians. The main objective of our research is to obtain hypotheses and predictions that can be tested in wet-lab or in clinical trials and thereby translate medical data into benefits in cancer patient care.
Read more
@HautaniemiLab

Excited to finally present our work “Deep neural networks identify signaling mechanisms of ErbB-family drug resista… twitter.com/i/web/status/1…

Online Now: Targeting pan-essential genes in cancer: challenges and opportunities dlvr.it/RqnKH6 https://t.co/AX7ETZnBRP

"Identifying key questions in the ecology and evolution of cancer": The (unformatted) final version of this article… twitter.com/i/web/status/1…

You are welcome to experience some brightness and warm breeze from Mexico in the middle of darkness: @rana_frog def… twitter.com/i/web/status/1…